General Information of Drug (ID: DMBHYIJ)

Drug Name
CI-992 Drug Info
Synonyms
CI-992; CHEMBL34894; 135704-06-2; CTK4B9950; N-[2-(2-Amino-thiazol-4-yl)-1-(1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-ethyl]-2-(morpholine-4-sulfonylamino)-3-phenyl-propionamide; L-Alaninamide,N-(4-morpholinylsulfonyl)-L-phenylalanyl-3-(2-amino-4-thiazolyl)-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-(9CI); BDBM50006844
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Terminated [1]
Cross-matching ID
PubChem CID
9875002
TTD Drug ID
DMBHYIJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Cathepsin D (CTSD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID10498202C1 DMXE0F2 Multiple sclerosis 8A40 Clinical trial [3]
Alpha-D-Mannose DMF5DLW Discovery agent N.A. Investigative [4]
Grassystatin a DM1PWX2 Discovery agent N.A. Investigative [5]
PMID8410973C3 DM6J5KY Discovery agent N.A. Investigative [6]
KNI-10006 DMMISH6 Discovery agent N.A. Investigative [7]
GRL-7234 DMR93MK Discovery agent N.A. Investigative [8]
S-Methylcysteine DMAMRKS Discovery agent N.A. Investigative [4]
Carbocyclic Peptidomimetic DM87SOX Discovery agent N.A. Investigative [9]
N-Aminoethylmorpholine DMWXBYC Discovery agent N.A. Investigative [4]
1h-Benoximidazole-2-Carboxylic Acid DMNZAVE Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin D (CTSD) TTPT2QI CATD_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002298)
2 Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. J Med Chem. 1992 Jul 10;35(14):2562-72.
3 Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2531-6.
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
6 Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
7 alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49.
8 Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407.
9 Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90.